Oct 7, 2010 by Brian Orelli, PhDThe U.K. Isn't NICE to Every Drug CompanyThe single-payer system strikes again.
Oct 6, 2010 by Brian Orelli, PhDWill Jazz's Rekinla Get FDA's OK?The company will likely need to address worries about the fibromyalgia treatment.
Oct 5, 2010 by Brian Orelli, PhDYou Should Have Seen this FDA Rejection ComingThis hepatitis C treatment was marked for failure.
Oct 1, 2010 by Brian Orelli, PhDThe Weekly Walk of Shame: Health-Care Reform ReduxSomeone didn't think this through.
Sep 30, 2010 by Brian Orelli, PhDThe One Thing You Need to Know About Eli LillyOne easy-to-read table tells it all.
Sep 30, 2010 by Brian Orelli, PhDBristol-Myers' Delayed StealZymoGenetics price tag looks more reasonable.
Sep 30, 2010 by Brian Orelli, PhDChief Justice Roberts Sold Pfizer. Should You?Maybe, but not for the same reason.
Sep 29, 2010 by Brian Orelli, PhDCareful What You Wish For, Stem Cell InvestorsInvestors seem to have forgotten about fundamentals.
Sep 29, 2010 by Brian Orelli, PhDBetter Buy: Spectrum Pharmaceuticals or Dendreon?A battle of the sales-ramping drugmakers.
Sep 29, 2010 by Brian Orelli, PhDMonsanto's SmartStax Isn't Stacking UpIt's hard to live up to the hype.
Sep 29, 2010 by Brian Orelli, PhDBoston Scientific: Strengths, Weaknesses, Opportunities, ThreatsGet the whole picture before investing.
Sep 28, 2010 by Brian Orelli, PhDDon't Get Stuck! Invest in Needle-Free DrugsHow to make money off trypanophobiacs.
